Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 75 microgram; ethinylestradiol, quantity: 40 microgram - tablet, sugar coated - excipient ingredients: povidone; lactose monohydrate; maize starch; montan wax; sucrose; magnesium stearate; macrogol 6000; calcium carbonate; purified talc - 1. oral contraception this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; indigo carmine; macrogol 6000; sucrose; glycol montanate; titanium dioxide; calcium carbonate; povidone; maize starch; lactose monohydrate; glycerol; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 1 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; glycerol; povidone; macrogol 6000; magnesium stearate; calcium carbonate; sucrose; titanium dioxide; glycol montanate; maize starch; purified talc; lactose monohydrate - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 125 microgram; ethinylestradiol, quantity: 50 microgram - tablet, sugar coated - excipient ingredients: calcium carbonate; magnesium stearate; purified talc; glycol montanate; lactose monohydrate; maize starch; macrogol 6000; sucrose; povidone - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: purified talc; lactose monohydrate; macrogol 6000; sucrose; povidone; magnesium stearate; calcium carbonate; maize starch; glycol montanate - oral contraception

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - bupivacaine hydrochloride; lignocaine as lignocaine hydrochloride; adrenaline-l-acid tartrate-d; cetrimide - topical cream, ointment, paste, gel, lotion - bupivacaine hydrochloride anaesthetic active 4.2 g/l; lignocaine as lignocaine hydrochloride anaesthetic active 40.6 g/l; adrenaline-l-acid tartrate-d hormone active 24.8 mg/l; cetrimide ammonium-quaternary active 5.0 g/l - anaesthetics/analgesics - lamb with mulesing wound - post surgical pain

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 19.5 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception for up to 5 years

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.